Fujian Boro Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Boro R&D") is a drug marketing authorization holder enterprise dedicated to investment management of the pharmaceutical industry chain (including the entire drug life cycle such as CRO, CMO/CDMO, CSO, etc.). It is a wholly-owned subsidiary of Fujian Boro Pharmaceutical Co., Ltd., established in May 2016 with a registered capital of 100 million yuan. It has won the honorary titles of National High-tech Enterprise, Science and Technology-based Small and Medium-sized Enterprises, and Fujian Province Innovative Small and Medium-sized Enterprises.

The company has a quality management center and a research and development laboratory center. Its quality management center takes quality from design as its concept and has established a complete quality management system to effectively manage the entire life cycle of drugs from project establishment, research and development, clinical trials, production and sales; the research and development laboratory center has a construction area of more than 1,000 square meters, and has introduced advanced domestic and foreign testing instruments and pilot production equipment, and has an efficient and professional pharmaceutical research and development team. The company mainly produces high-end preparations (sustained and controlled release dosage forms), injections, and external dosage forms. Since its establishment, the company has 6 approval documents and more than 30 varieties under development. The products mainly involve cardiovascular and cerebrovascular, neuropsychiatric, common diseases of the elderly, chronic diseases and other fields.

As a modern pharmaceutical R&D investment and management company, the company has always taken "always being in awe and creating quality medicines" as its mission, adhered to the concept of "collaborative efficiency and scientific development", embraced internationalization and cared for health.